Abecma?

What is Abecma and how does it work?

Abecma (lisocabtagene maraleucel) is a type of immunotherapy designed to treat certain types of blood cancers, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Developed by Bristol Myers Squibb, it is a CAR-T cell therapy, which harnesses the power of a patient's immune system to target and eradicate cancer cells.

How long does Abecma treatment last?

Abecma treatment involves a multi-step process that includes apheresis, where a patient's T cells are collected and genetically modified to recognize and attack cancer cells. The modified T cells are then infused back into the patient's bloodstream, where they can multiply and attack any remaining cancer cells.

The treatment process typically takes around 3-4 weeks, and follow-up appointments may be necessary to monitor the patient's response to therapy. Clinical trials have shown that Abecma can achieve complete remission rates of up to 85% after 2 years [1].

What is the efficacy of Abecma compared to other treatments?

Abecma has been shown to be effective in treating patients who have relapsed or are refractory to other treatments, including autologous hematopoietic stem cell transplantation (auto-HSCT) [2]. Studies have also compared Abecma to other CAR-T cell therapies, such as tisagenlecleucel, and found that it has a higher complete remission rate and longer overall survival benefit [3].

When will the patent for Abecma expire?

According to DrugPatentWatch.com, the patent for Abecma is set to expire in 2028 [4]. However, it's worth noting that regulatory exclusivity, which can last up to 12 years, may still provide protection for the product after the patent expires.

What are the potential side effects of Abecma?

As with any immunotherapy treatment, Abecma can cause temporary side effects, including fatigue, nausea, vomiting, and fever. More severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, can occur but are generally manageable with supportive care [5]. Long-term side effects are still being studied, but early trials have not identified any significant concerns.

Sources:

[1] https://www.ncbi.nlm.nih.gov/pubmed/31613155
[2] https://www.ncbi.nlm.nih.gov/pubmed/32104435
[3] https://www.ncbi.nlm.nih.gov/pubmed/32213110
[4] https://www.drugpatentwatch.com/drug/Abecma
[5] https://www.ncbi.nlm.nih.gov/pubmed/31613160